Neurocrine Biosciences, Inc. (NBIX)
Healthcare • Drug Manufacturers - Specialty & Generic
StockNasdaqGSUnited StatesUS64125C1099
165.03 USD
-2.58% today Updated 13 Nov 2026 16:11
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Neurocrine Biosciences, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:11. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
11 Feb 2027
in 90 days · 16:00 · estimate 2.77
Last results
3.29 vs 2.75 estimated
02 Nov 2026 · Beat +19.8%
Beat the estimate
7 of 12
4 missed · 1 in line · 3 beats in a row
Average surprise
+2.4%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 11 Feb 2027 16:00 | 2.77 | — | — | Upcoming |
| 02 Nov 2026 16:00 | 2.75 | 3.29 | +19.8% | Beat |
| 30 Jul 2026 16:00 | 1.96 | 2.85 | +45.4% | Beat |
| 05 May 2026 16:00 | 1.70 | 1.94 | +14.4% | Beat |
| 11 Feb 2026 16:00 | 2.30 | 1.88 | -18.1% | Miss |
| 28 Oct 2025 16:00 | 2.07 | 2.17 | +4.9% | Beat |
| 30 Jul 2025 16:00 | 1.50 | 1.65 | +9.6% | Beat |
| 05 May 2025 16:00 | 1.09 | 0.70 | -36.0% | Miss |
| 06 Feb 2025 16:00 | 1.93 | 1.69 | -12.4% | Miss |
| 30 Oct 2024 07:00 | 1.82 | 1.81 | -0.4% | In line |
| 01 Aug 2024 07:00 | 1.53 | 1.63 | +6.8% | Beat |
| 01 May 2024 07:00 | 1.29 | 1.20 | -6.8% | Miss |
| 07 Feb 2024 07:00 | 1.51 | 1.54 | +1.7% | Beat |
| 31 Oct 2023 07:00 | 1.33 | 1.54 | +15.8% | Beat |
| 01 Aug 2023 07:00 | 1.12 | 1.25 | +11.7% | Beat |
| 03 May 2023 07:00 | 0.74 | -0.51 | -169.4% | Miss |
| 06 Feb 2023 07:00 | 1.44 | 1.24 | -14.1% | Miss |
| 01 Nov 2022 07:00 | 1.12 | 1.08 | -3.7% | Miss |
| 04 Aug 2022 16:00 | 0.89 | 0.84 | -5.7% | Miss |
| 04 May 2022 07:00 | 0.59 | 0.30 | -49.3% | Miss |
| 11 Feb 2022 07:00 | 0.88 | 0.04 | -95.5% | Miss |
| 01 Nov 2021 16:00 | 0.80 | 0.64 | -19.6% | Miss |
| 03 Aug 2021 16:00 | 0.76 | 0.63 | -16.8% | Miss |
| 05 May 2021 16:00 | 0.72 | 0.49 | -31.8% | Miss |
| 04 Feb 2021 16:00 | 0.90 | 0.91 | +1.1% | Beat |
| 09 Nov 2020 16:00 | 1.25 | 0.97 | -22.3% | Miss |
| 03 Aug 2020 16:00 | 1.02 | 1.42 | +39.1% | Beat |
| 06 May 2020 17:00 | 0.64 | 0.82 | +28.9% | Beat |
| 04 Feb 2020 16:00 | 0.75 | 0.35 | -53.3% | Miss |
| 04 Nov 2019 16:00 | 0.64 | 0.56 | -12.9% | Miss |
| 29 Jul 2019 16:00 | 0.25 | 0.54 | +112.6% | Beat |
| 29 Apr 2019 16:00 | -0.89 | -1.12 | -26.0% | Miss |
| 05 Feb 2019 16:00 | 0.19 | 0.19 | -0.5% | In line |
| 05 Nov 2018 16:00 | 0.49 | 0.52 | +5.4% | Beat |
| 31 Jul 2018 16:00 | -0.18 | -0.07 | +60.4% | Beat |
| 30 Apr 2018 16:00 | -0.30 | -0.47 | -56.7% | Miss |
| 13 Feb 2018 16:00 | 0.16 | 0.07 | -56.7% | Miss |
| 01 Nov 2017 16:00 | -0.53 | -0.13 | +75.3% | Beat |
| 03 Aug 2017 16:00 | -0.65 | -0.68 | -4.8% | Miss |
| 09 May 2017 16:00 | -0.72 | -0.90 | -25.3% | Miss |
| 14 Feb 2017 16:00 | -0.55 | -0.51 | +7.6% | Beat |
| 02 Nov 2016 16:00 | -0.57 | -0.43 | +24.2% | Beat |
| 03 Aug 2016 16:00 | -0.49 | -0.46 | +6.7% | Beat |
| 05 May 2016 16:00 | -0.31 | -0.22 | +28.6% | Beat |
| 11 Feb 2016 16:00 | -0.35 | -0.34 | +3.6% | Beat |
| 29 Oct 2015 16:00 | -0.32 | -0.40 | -24.4% | Miss |
| 29 Jul 2015 16:00 | -0.29 | -0.28 | +4.4% | Beat |
| 30 Apr 2015 07:00 | -0.30 | -0.01 | +96.7% | Beat |
| 09 Feb 2015 16:00 | -0.24 | -0.26 | -7.6% | Miss |
| 03 Nov 2014 16:00 | -0.20 | -0.21 | -2.8% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 2.9B | +21.4% | 478.6M | 16.7% | 4.67 | +41.9% | 748.7M |
| 2024 | 2.4B | +24.8% | 341.3M | 14.5% | 3.29 | +33.2% | 557.2M |
| 2023 | 1.9B | +26.8% | 249.7M | 13.2% | 2.47 | +58.3% | 361.6M |
| 2022 | 1.5B | — | 154.5M | 10.4% | 1.56 | — | 322.9M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 145.70 | 174.59 | 143.75 | 165.03 | +12.96% | 16,666,576 | |
| Oct 2026 | 140.94 | 149.25 | 132.25 | 146.10 | +3.00% | 28,081,500 | |
| Sep 2026 | 154.31 | 160.43 | 136.31 | 141.84 | -7.91% | 25,846,500 | |
| Aug 2026 | 166.25 | 170.88 | 148.78 | 154.03 | -7.66% | 25,660,900 | |
| Jul 2026 | 169.50 | 186.12 | 164.56 | 166.80 | -1.03% | 28,768,000 | |
| Jun 2026 | 159.36 | 171.50 | 154.06 | 168.54 | +6.47% | 25,917,800 | |
| May 2026 | 131.79 | 162.39 | 129.86 | 158.30 | +20.22% | 25,777,500 | |
| Apr 2026 | 131.93 | 134.20 | 125.31 | 131.67 | -0.05% | 24,745,500 | |
| Mar 2026 | 130.32 | 134.83 | 125.11 | 131.74 | -0.39% | 21,873,500 | |
| Feb 2026 | 135.33 | 142.82 | 122.14 | 132.25 | -2.80% | 25,366,700 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference (opens in a new tab) 10 Nov 2026 21:01
- NBIX or GRDN: Which Is the Better Value Stock Right Now? (opens in a new tab) Zacks · 10 Nov 2026 19:38
- Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice (opens in a new tab) Zacks · 09 Nov 2026 16:45
- All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy (opens in a new tab) Zacks · 09 Nov 2026 16:00
- NBIX vs. GRDN: Which Stock Is the Better Value Option? (opens in a new tab) Zacks · 09 Nov 2026 15:40
- Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High? (opens in a new tab) Zacks · 09 Nov 2026 13:55
- Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules (opens in a new tab) 05 Nov 2026 13:30
- Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules (opens in a new tab) Benzinga · 05 Nov 2026 09:37
- Neurocrine Biosciences: Breaking Down A Solid Quarter (opens in a new tab) SeekingAlpha · 05 Nov 2026 04:05
- Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224 (opens in a new tab) Benzinga · 04 Nov 2026 11:20
- Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation (opens in a new tab) SeekingAlpha · 04 Nov 2026 10:05
- Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free (opens in a new tab) SeekingAlpha · 04 Nov 2026 08:45
- Neurocrine Biosciences, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 04 Nov 2026 01:29
- Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress (opens in a new tab) 03 Nov 2026 21:05
- Is Neurocrine Biosciences (NBIX) A Bargain On Raised INGREZZA Guidance? (opens in a new tab) Simply Wall St. · 03 Nov 2026 20:09
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 169.40 USD
- Market cap
- 16.7B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow NBIX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.